Brief: Beam Therapeutics Says It Sets Strategic Priorities For Its Genetic Disease & Hematology Franchises
11/01/2026 22:05
Jan 11 (Reuters) - Beam Therapeutics Inc BEAM.O: BEAM THERAPEUTICS SETS STRATEGIC PRIORITIES FOR ITS GENETIC DISEASE AND HEMATOLOGY FRANCHISES TO DRIVE EXECUTION OF LATE-STAGE CLINICAL PROGRAMS AND EXTENDS ITS OPERATING RUNWAY THROUGH COMMERCIAL TRANSITION BEAM THERAPEUTICS INC - FDA ALIGNMENT ON ACCELERATED APPROVAL PATHWAY FOR BEAM-302 BEAM THERAPEUTICS INC - RISTO-CEL BLA SUBMISSION EXPECTED BY YEAR-END 2026 BEAM THERAPEUTICS INC - TO ANNOUNCE NEW LIVER-TARGETED PROGRAM IN H1 2026 Source text: ID:nGNX4ct14z Further company coverage: BEAM.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Beam Therapeutics
See all newsBeam Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Beam Therapeutics Q1 net loss narrows beating analyst estimates
U.S. STOCKS ON THE MOVE-ADMA Biologics, Nanobiotix, DraftKings
U.S. STOCKS ON THE MOVE-BWX, Generac, Cintas
U.S. STOCKS ON THE MOVE-Arm, On Holding, Sarepta